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Abstract
Background: Herpes zoster (HZ) is caused by a reactivation of the varicella-zoster-virus (VZV) and mainly affects
individuals aged ≥ 50 years. Vaccines have been licensed or are under development that can protect against HZ
and its main complication postherpetic neuralgia (PHN). In Germany, the burden of disease caused by HZ is not
well known. To support the decision making process related to a potential vaccination recommendation, we
estimated annual HZ disease burden in people aged ≥ 50 years in Germany by utilizing various data sources.
Methods: We assessed for 2007 and 2008 HZ-outpatient incidence (number of cases per 1,000 person-years, PY) by
utilizing the Association of Statutory Health Insurance Physicians (ASHIP) database, which contains nationwide
routine outpatient data. For the same time period annual number of HZ-inpatients and HZ-associated deaths were
identified by using the Federal Health Monitoring System (FHM). PHN-incidence and loss of quality-adjusted life
years (QALYs) caused by HZ were calculated by multiplying number of identified HZ-patients with upper and lower
limit estimates for proportion of HZ-cases developing PHN and HZ-related QALY, respectively.
Results: For the study period we identified an annual average of 306,511 HZ-outpatients aged 50+, resulting in a
HZ-incidence of 9.6/1,000 PY. A total 14,249 HZ-associated inpatients and 66 deaths were reported in both years
on average. HZ-incidence increased by age from 6.21 in people 50-54 years to 13.19 per 1,000 PY in people aged
≥ 90 years. Females were significantly more frequently affected than males in terms of outpatient HZ-incidence
(11.12 vs. 7.8 per 1,000 PY), inpatient HZ-incidence (0.51 vs. 0.38 per 1,000 PY) and mortality (0.29 vs. 0.10 per
100,000 PY). PHN-incidence was estimated to range between 0.43 and 1.33 per 1,000 PY. Based on these figures,
there were between 3,065 to 24,094 QALYs lost due to HZ in persons aged ≥ 50 years in Germany per annum.
Conclusion: Our study provides important baseline estimates for HZ-related disease burden in Germany. HZ poses
a considerable burden on the health care system in Germany both in terms of outpatient and inpatient services.
Follow-up assessments of HZ disease burden are needed to monitor the impact of VZV-vaccinations in Germany.
Background
Infection with the varicella-zoster-virus (VZV) usually
occurs in childhood and causes chickenpox [1]. The
virus persists lifelong in the dorsal roots of the cranial
and spinal ganglia of humans. Especially in the elderly,
the virus can reactivate as herpes zoster (HZ) due to
decreasing VZV-specific T-cell-immunity [2,3]. Besides a
20-30% risk of developing HZ over lifetime, the risk of
HZ increases distinctly from the fifth decade in life
[1,4-6]. The main complication of HZ is postherpetic
neuralgia (PHN), a long-lasting and occasionally recur-
ring pain [3,6,7]. Both HZ and PHN cause limitation of
the quality of life of affected individuals [8-11].
Thitherto the current treatment options of HZ and the
prevention of PHN are not always optimal [12-14].
One vaccine for the protection against the manifesta-
tion of HZ and PHN is currently in late-stage develop-
ment; another HZ vaccine has recently been licensed in
the US and in Europe [15,16]. The licensed vaccine has
demonstrated its efficacy in preventing HZ and PHN in
a randomized double-blind, placebo-controlled trail
involving almost 40,000 individuals 60 years of age and
older. HZ and PHN-incidences were reduced in this
study by approximately 51% and 67%, respectively [17].
As of yet the duration of protection was demonstrated
to last at least 7 years [18]. Furthermore, the vaccine
has demonstrated an acceptable safety profile in
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as in people 60 years and older [19]. Based on these
findings, the European Medicine Agency approved the
first HZ vaccine in 2006 for immune-competent indivi-
duals sixty years of age and older, which was later chan-
ged to 50 years of age and older [16].
Germany does not have a national surveillance system
in place for HZ, and therefore country-level data on the
epidemiology of HZ and PHN are scarce. To support
the decision making process related to a potential HZ-
vaccination recommendation in the elderly we aimed to
estimate annual HZ and PHN disease burden in people
aged ≥ 50 years in Germany by utilizing various data
sources. Since routine childhood varicella vaccination
has been carried out in Germany since 2004, baseline
HZ disease burden data are also urgently needed to
monitor the impact of varicella vaccination on HZ epi-
demiology [20,21].
Methods
Study design
We assessed HZ-incidence (number of cases per 1,000
person-years, PY) in Germany by utilizing different data
bases containing routine patient-related diagnosis data.
All individuals aged ≥ 50 years with a diagnosis of acute
HZ in 2007 or 2008 identified in the data bases were
included in the analysis and stratified by 5-year age-
groups and gender. Since the immune status was not
documented in any of the utilised data bases, immune-
compromised individuals were not excluded from our
analyses.
HZ disease burden in outpatients
The Association of Statutory Health Insurance Physi-
cians (ASHIP) database contains nationwide routine
outpatient data, documented by each of the 17 regional
ASHIPs in Germany. The ASHIP covers all patients
who are insured in the statutory health insurance (SHI)
in Germany. In the SHI approximately 90% of all people
living in Germany are insured. All practitioners send
billing data for medical services to their regional ASHIP
o naq u a r t e r l yb a s i s .T h e s ed a t aw e r ep s e u d o n y m i z e d
and imported into a SQL server database at the Robert
Koch Institute (RKI). It contains the patients’ age, gen-
der, year and quarter of diagnosis, International Classifi-
cation of Diseases (ICD)-10 codes, reliability of
diagnosis as indicated by the physician (assured or sus-
pected diagnosis, status after disease, disease excluded,
or unknown), and ASHIP region. All patients with a
HZ-related diagnosis code (ICD-10: B02.*) and with an
‘assured’ or ‘suspected’ reliability of diagnosis were
included in the analysis (Table 1). Individuals with an
undocumented gender were distributed proportionally
to both genders according to the gender-proportion
among individuals with available information in each
age-group.
In our analysis we utilized a sample that covered in
2007 approximately 69% (14 ASHIPs) and in 2008
approximately 52% (eleven ASHIPs) of the total German
population, respectively. For each of the two years we
assessed the incidence of acute HZ treated as outpati-
ents by using a cohort design: Since patients have a
unique identifier in the ASHIP dataset they can be indi-
vidually followed up over time. Therefore, to identify
and exclude non-acute HZ-cases in 2007 we used the
ASHIP dataset of 2006, and to identify non-acute outpa-
tient HZ-cases in 2008 we used the 2007-dataset.
Results from both years were extrapolated from the
samples to the total population in Germany. Afterwards
a weighted average was calculated for the incidence and
number of HZ cases on a national level for the study
period 2007-2008.
HZ-associated hospitalization and mortality
We used the information system of the Federal Health
Monitoring System (FHM) to assess the annual number
of HZ-associated deaths and HZ-inpatients and used
these data to calculate the mortality and incidence of
HZ leading to hospitalisation in people aged ≥ 50 years.
The FHM contains more than 605 million data from
over 100 sources provided by the statistical offices of
the federal states and the federation as well as data from
the federal ministry of health, statutory health insur-
ances, and the Robert Koch Institute [22,23].
The federal statistic office supplies ICD-10 related
main diagnosis hospital statistics and ICD-10 related
statistics on the primary cause of death in Germany.
Table 1 Number of cases and proportion of HZ diagnoses
(ICD-10 codes
a) in the weighted study sample, 2007/2008
ICD-10
Code
Number of
cases
b
Proportion
(%)
Description
B02.- 6 0.00 Zoster [herpes zoster] Includes:
shingles/zona
B02.0 734 0.39 Zoster encephalitis/Zoster
meningoencephalitis
B02.1 47 0.02 Zoster meningitis
B02.2 25,654 13.48 Zoster with other nervous
system involvement
B02.3 8,181 4.30 Zoster ocular disease
B02.7 1,100 0.58 Zoster generalisatus
B02.8 7,122 3.74 Zoster with other complications
B02.9 147,514 77.49 Zoster without complication
(e.g. Zoster NOS)
total 190,358 100.00
NOS = not otherwise specified
aWorld Health Organisation [46]
bWeighted average from study samples 2007 and 2008 - without
extrapolation
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data of all inpatients in all German hospitals. Among
others, characteristics like gender, month and year of
birth, date of hospitalization and discharge, and main
diagnosis (ICD-10 code) are available for each patient
[23]. For each death reported in the FHM system, infor-
mation on gender, age group, and the ICD code of the
primary disease of the deceased person (as documented
by the physician who recorded the death) are documen-
ted [23].
We extracted number of hospitalized patients with a
main diagnosis of HZ and the number of deaths, where
the primary disease of the deceased person was HZ, in
persons ≥ 50 years of age for 2007 and 2008, stratified
by age and gender, and calculated a weighted average
for our study period 2007-2008.
HZ-associated complications and quality of life loss
Since there was a lack of patient-related information on
PHN in the available data sources, we estimated the
total number of PHN patients in Germany by applying a
PHN-proportion (i.e. the average proportion of HZ-
patients developing PHN) to the estimated total number
of HZ-outpatients in 2007-2008. For each age-group
(50-54, 55-59, etc.) we used a minimum and maximum
estimate of the PHN-proportion based on available lit-
erature. Since there is no unique definition of PHN, we
defined PHN as pain lasting at least three months after
HZ rash onset (PHN3), which is commonly used in lit-
erature [17,24-30]. We identified three publications indi-
cating the proportion of HZ-cases developing PHN3:
Opstelten et al. found a proportion of 0.8% in 50-54
year-olds, which increased to 9% in HZ-patients aged ≥
90 year [27]. Schiffner-Rohe et al. presented a propor-
tion of 4.4% among 50-54 year-old HZ-patients which
increased to 7.7% in patients 90 years and older [28].
Finally, Gauthier et al. found a range in HZ-patients
from 8% (50-54 year-olds) to 19% (90 years and older)
[25]. Based on these figures we calculated an upper and
lower limit estimate of PHN disease burden in Germany.
Other HZ-associated complications (e.g. HZ meningitis
or ocular disease) were identified by the respective ICD-
10 codes in the ASHIP database (Table 1).
For Germany, HZ-related quality of life (QoL) data are
missing. To calculate the loss of quality-adjusted life
years (QALY) caused by HZ in Germany, we multiplied
t h eQ A L Yl o s sp e rH Z - c a s ef o u n di ns t u d i e sf r o m
Canada, the United Kingdom, and Wales with the num-
ber of HZ-outpatients, which we identified in our
ASHIP database and extrapolated to the total population
in Germany [24,29,31]. Edmunds et al. found in the
United Kingdom and Wales a QALY loss per HZ case
of 0.01 for all age-groups 50 years and above [31]. In
the other two studies, QALYs lost per HZ case
increased by age from 0.01 to 0.11 and from 0.026 to
0.200 in the age-groups 50-54 to ≥ 90 years, respectively
[24,29]. Based on these values, an upper and lower limit
estimate for QALY loss per age-group due to HZ was
calculated for the population in Germany.
Statistical methods
We used PASW 17 (SPSS, Somers, NY), Stata 11 (Stata,
College Station, TX), Microsoft Excel 2003 and Micro-
soft SQL Server Management Studio 2008 (Microsoft,
Redmond, WA) for data management and analysis, and
calculated 95% Poisson confidence intervals for all
values except QALYs.
Results
HZ in outpatients in the study sample and country-level
estimates
A total of 210,310 and 164,335 outpatients aged ≥ 50
years with an acute HZ diagnosis were identified in the
ASHIP sample in 2007 and 2008 respectively (Table 2).
Table 2 Number of Herpes Zoster (HZ) outpatient cases and HZ-incidence in the study sample, 2007 and 2008
Outpatient HZ cases (study sample) 2007 Outpatient HZ cases (study sample) 2008
Age-group (years) Population Cases Incidence
a CI (95%) Population Cases Incidence
a CI (95%)
50 - 54 3,751,003 23,285 6.21 6.13 - 6.29 2,881,754 18,396 6.38 6.29 - 6.48
55 - 59 3,435,593 26,224 7.63 7.54 - 7.73 2,671,483 20,655 7.73 7.63 - 7.84
60 - 64 2,799,252 25,341 9.05 8.94 - 9.17 2,136,220 19,224 9.00 8.87 - 9.13
65 - 69 3,673,692 39,190 10.67 10.56 - 10.77 2,688,120 29,172 10.85 10.73 - 10.98
70 - 74 3,010,534 33,776 11.22 11.10 - 11.34 2,430,392 27,943 11.50 11.36 - 11.63
75 - 79 2,229,980 26,820 12.03 11.88 - 12.17 1,644,341 20,252 12.32 12.15 - 12.49
80 - 84 1,598,890 19,912 12.45 12.28 - 12.63 1,233,658 15,603 12.65 12.45 - 12.85
85 - 89 889,002 10,935 12.30 12.07 - 12.53 731,191 9,375 12.82 12.56 - 13.08
90+ 376,927 4,827 12.81 12.45 - 13.17 269,752 3,715 13.77 13.33 - 14.22
total 21,764,873 210,310 9.66 9.62 - 9.70 16,686,911 164,335 9.85 9.80 - 9.90
CI = confidence interval
acases per 1,000 person-years
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diagnose reliability “confirmed” was about 90% (with the
remaining 10% being “suspected”). Among identified
HZ-cases, the proportion of individuals with an undocu-
mented gender remained in both years below 6%. The
most frequently coded ICD-10 with approximately 77%
was B02.9 (HZ without complication) followed by B02.2
(HZ with other nervous system involvement) with
almost 13%. HZ with ocular involvement (B02.3) was
coded in approximately 4% of HZ-cases (Table 1).
Extrapolating results of the study sample to the total
German population aged ≥ 50 years revealed 300,511
cases and 312,002 HZ outpatient cases for 2007 and
2008, respectively. These figures result in a weighted
annual average of 306,511 patients or 9.60 per 1,000 PY
treated for acute HZ in an outpatient facility in Ger-
many 2007-2008 (Table 3). HZ-incidence increased with
age: In the age-group 50-54 years average HZ outpati-
ents incidence was 6.21 per 1,000 PY and increased to
13.19 in persons 90 years and older. Comparing indivi-
duals in their 70s with people between 50 and 54 years
of age the incidence almost doubled within two decades
(Table 3).
Females were significantly more frequently affected by
HZ. Of all HZ-cases identified in the ASHIP samples
approximately 65% were females. Overall HZ-incidence
in females and males was estimated at 11.12 and 7.80
per 1,000 PY, respectively. The age-dependency of the
incidence existed in both genders (Table 3).
Hospitalization and mortality due to HZ
The FHM data base contained 14,181 and 14,273 inpati-
ent HZ-cases in 2007 and 2008, respectively. This
results in a weighted average of 14,249 HZ-related inpa-
tients in the study period 2007-2008. Between age-group
50-54 and 90+ years, incidence of HZ-associated hospi-
talization increased from 0.13 to 1.08 per 1,000 PY
(Table 4). Of hospitalized HZ-cases aged ≥ 50 years 62%
were female. The incidence of HZ leading to hospitalisa-
tion was 0.51 per 1,000 PY in females and 0.38 in males.
An age-dependent increase in hospitalization incidence
was identified in both males and females (Table 4).
For 2007 and 2008, in total 69 and 56 deaths were
reported to be caused by HZ, respectively. The weighted
average was 66 individuals aged ≥ 50 years, who were
reported as deaths due to HZ in 2007-2008, which
translated in a mortality of 0.21 per 100,000 PY. Forty-
eight (73%) of the deceased HZ-patients were ≥ 80 years
of age, and mortality increased with age from 0.02/
100,000 (age-group 50-54) to 3.86/100,000 (age-group ≥
90 years) (Table 5). The number of deaths was more
than 3-times higher in females, with a weighted average
of 51 compared to 15 in males.
Complication and quality of life loss
When applying upper and lower limit estimates for the
proportion of HZ-cases developing PHN by age-group,
the overall PHN-incidence for Germany was estimated
to range between 0.43 and 1.33 per 1,000 PY in indivi-
duals aged ≥ 50 years (Table 5). The annual QALY loss
due to HZ in individuals 50 years and older in Germany
was estimated to range between 3,065 and 24,094 (Table
5).
Discussion
Our study provides the first nationwide estimates of
annual disease burden caused by HZ and PHN in Ger-
many. We derived these estimates from a comprehen-
sive physician database that covers approximately 60%
of the total German population 50 years of age and
Table 3 Weighted annual average HZ-incidence extrapolated on the total German population
a, 2007/2008
Total Male Female
age group (years) Population Cases Incidence
b CI (95%) Incidence
c CI (95%) Incidence
d CI (95%)
50 - 54 5,831,377 36,220 6.21 6.15 - 6.28 4.64 4.57 - 4.72 7.80 7.70 - 7.90
55 - 59 5,305,382 40,274 7.59 7.52 - 7.67 5.84 5.75 - 5.94 9.31 9.19 - 9.43
60 - 64 4,225,970 37,769 8.94 8.85 - 9.03 7.22 7.11 - 7.34 10.59 10.46 - 10.73
65 - 69 5,218,814 55,816 10.70 10.61 - 10.78 8.95 8.84 - 9.07 12.30 12.17 - 12.43
70 - 74 4,362,971 49,473 11.34 11.24 - 11.44 9.87 9.74 - 10.01 12.59 12.44 - 12.73
75 - 79 3,014,860 36,633 12.15 12.03 - 12.28 10.96 10.78 - 11.15 13.02 12.85 - 13.19
80 - 84 2,219,495 27,810 12.53 12.38 - 12.68 11.35 11.11 - 11.59 13.15 12.96 - 13.33
85 - 89 1,247,016 15,684 12.58 12.38 - 12.78 11.65 11.29 - 12.03 12.91 12.68 - 13.15
90+ 518,045 6,832 13.19 12.88 - 13.51 11.99 11.39 - 12.61 13.58 13.21 - 13.96
total 31,943,930 306,511 9.60 9.56 - 9.63 7.80 7.75 - 7.84 11.12 11.07 - 11.17
CI = confidence interval
aweighted average based on extrapolated study samples 2007 and 2008
bcases per 1,000 person-years
ccases per 1,000 males and year
dcases per 1,000 females and year
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aged ≥ 50 years, HZ poses a considerable burden to the
health care system in Germany both in terms of outpati-
ent and inpatient services. The increase in disease inci-
dence and HZ-associated mortality with age reconfirms
the remarkable affection of the elderly. And due to the
d e m o g r a p h i ca g i n gi nG e r m a n yi ti sl i k e l yt h a tH Zd i s -
ease burden will further increase in the future.
The magnitude of incidence observed in our study is
consistent with previously published reports from Ger-
many and other European countries. In 1992/93, HZ-
incidence in the district of Ansbach, Germany, was
found to be 3.41 per 1,000 PY in people ≥ 50 years, and
a study conducted in the German federal state of Hesse
revealed an incidence of 9.40 per 1,000 PY in 2004
[28,32]. Studies from other European countries demon-
strated incidences ranging from 5.23 to 8.93 per 1,000
in the same age-group [25,26,31,33,34]. In Australia, an
incidence range of 9,70 to 10.10 HZ-cases per 1,000 PY
in people 50 years and over was reported [35]. A rando-
mised clinical trial, conducted 1998-2001 in the US to
assess the efficacy of a HZ candidate vaccine, revealed
an incidence of 11.12 per 1,000 PY but including only
individuals aged ≥ 60 years [17]. A systematic literature
Table 4 Weighted annual average of total number of cases and incidence of Herpes Zoster (HZ) leading to
hospitalization, Germany, 2007/2008
Total Male Female
age group (years) Population Cases Incidence
a CI (95%) Incidence
b CI (95%) Incidence
c CI (95%)
50 - 54 5,831,377 754 0.13 0.12 - 0.14 0.11 0.10 - 0.18 0.14 0.13 - 0.16
55 - 59 5,305,382 1,040 0.20 0.18 - 0.21 0.16 0.15 - 0.18 0.23 0.21 - 0.25
60 - 64 4,225,970 1,296 0.31 0.29 - 0.32 0.28 0.25 - 0.30 0.34 0.31 - 0.36
65 - 69 5,218,814 2,299 0.44 0.42 - 0.46 0.41 0.38 - 0.43 0.47 0.45 - 0.50
70 - 74 4,362,971 2,394 0.55 0.53 - 0.57 0.52 0.49 - 0.56 0.57 0.54 - 0.60
75 - 79 3,014,860 2,381 0.79 0.76 - 0.82 0.76 0.71 - 0.81 0.81 0.77 - 0.86
80 - 84 2,219,495 2,196 0.99 0.95 - 1.03 0.92 0.85 - 0.99 1.03 0.98 - 1.08
85 - 89 1,247,016 1,330 1.07 1.01 - 1.13 1.00 0.89 - 1.11 1.09 1.03 - 1.16
90+ 518,045 559 1.08 0.99 - 1.17 0.90 0.74 - 1.08 1.14 1.04 - 1.25
Total 31,943,930 14,249 0.45 0.44 - 0.45 0.38 0.37 - 0.39 0.51 0.50 - 0.52
CI = confidence interval
acases per 1,000 person-years
bcases per 1,000 males and year
ccases per 1,000 females and year
Table 5 Annual deaths, PHN3
a incidence and QALY
b loss due to Herpes Zoster (HZ) in Germany
c, 2007/2008
Deaths PHN incidence based on different szenarios
d QALY loss due to HZ
Min Max
age group (years) Deaths mortality rate
e CI (95%) Incidence
f CI (95%) Incidence
f CI (95%) Min
g Max
g
50 - 54 1 0.02 0.00 - 0.10 0.05 0.04 - 0.06 0.50 0.48 - 0.52 362 942
55 - 59 0 0.00 NA 0.22 0.21 - 0.23 0.76 0.74 - 0.78 403 1,047
60 - 64 1 0.02 0.00 - 0.13 0.26 0.24 - 0.28 0.98 0.95 - 1.01 378 2,531
65 - 69 3 0.06 0.01 - 0.17 0.35 0.34 - 0.37 1.39 1.36 - 1.42 558 3,740
70 - 74 5 0.11 0.04 - 0.27 0.37 0.36 - 0.39 1.70 1.66 - 1.74 495 5,442
75 - 79 9 0.30 0.14 - 0.57 0.78 0.75 - 0.81 2.19 2.14 - 2.24 366 4,030
80 - 84 12 0.54 0.28 - 0.94 0.96 0.92 - 1.01 2.63 2.56 - 2.70 278 5,562
85 - 89 15 1.20 0.67 - 1.98 0.97 0.92- 1.03 2.39 2.31 - 2.48 157 3,137
90+ 20 3.86 2.36 - 5.96 1.02 0.93 - 1.11 2.51 2.37 - 2.65 68 1,366
total 66 0.21 0.16 - 0.26 0.43 0.43 - 0.44 1.33 1.32 - 1.34 3,065 24,094
CI = confidence interval; NA = not applicable
apostherpetic neuralgia lasting over three months after HZ diagnosis.
bquality-adjusted life year.
cextrapolation on living population in Germany based on study sample
ddata based on Schiffner-Rohe et al. 2010 [28], Gauthier et al. 2009 [25], Opstelten et al. 2002 [27].
edeaths per 100,000 person-years.
fcases per 1,000 person-years.
gdata based on van Hoek et al. 2009 [29], Brisson et al. 2008 [24], Edmunds et al. 2001 [31].
Ultsch et al. BMC Infectious Diseases 2011, 11:173
http://www.biomedcentral.com/1471-2334/11/173
Page 5 of 8review concerning HZ incidence in people 60 years and
over identified an incidence range of 3.6 to 14.2 per
1,000 PY [36]. Even though the incidences observed in
different study settings were in a rather similar magni-
tude, the burden posed to the healthcare systems in the
individual countries might vary considerably due to dif-
ference in the systems.
The remarkable increase in HZ-incidence by age can
be explained with waning VZV-immunity [2,3]. The
observed difference in sex-distribution remains, how-
ever, unclear. Several other studies reported in accor-
dance to our assessment a higher incidence in females,
e.g. in France, Germany, Italy, and the US [17,25,26,
28,34,37,38]. It has been suggested, that there might be
a difference in the immune response to latent viral
infection among women and men, but the exact
mechanisms are unknown [38].
An average annual 66 deaths due to HZ was reported
within the FHM database we utilized, resulting in a
mortality of 0.02 deaths per 100,000 PY (age-group 50-
54) to 3.86 deaths per 100,000 PY (in 90 years and
over), which is lower than estimated in France, where
mortality ranges from 0.072 (age-group 55-64 years) to
19.48 deaths per 100,000 PY in people over the age of
94 [26]. Differences in the reporting system might be a
reason for this discrepancy.
Our assessment of QALYs is limited by the fact that
HZ-related QoL estimates for Germany were not avail-
able. However, the countries from where the QoL esti-
mates were derived seem fairly similar to Germany as
far as demographics and health care standard are con-
cerned [24,29,31]. Values concerning QALY loss may
differ intensely as they depend on epidemiology, popula-
tion, evaluation technique, and the general setting in
which those values were surveyed [39]. We accounted
for the resulting uncertainty by calculating a range con-
sisting of lower and upper limit estimates. Annual
QALY losses caused by other major diseases in Ger-
many have been published previously. For example,
osteoporosis-attributable hip fractures were estimated to
c a u s em o r et h a n6 6 , 0 0 0Q A L Y sl o s ti nG e r m a n yi n
2002, and obesity almost 370,000 QALYs [40,41]. Due
to the fact that high disease incidence leading to consid-
erable QALY loss, HZ can be regarded - even without
considering QALY loss caused by PHN - as a relevant
public health problem in Germany.
The use of the ASHIP and FHM databases may, how-
ever, cause some limitations. None of the two databases
provided information on PHN, which is the most
important complication of HZ and therefore crucial for
estimating HZ disease burden [6,31]. By utilizing pub-
lished literature we compensated this data gap. The true
PHN3-incidence for the population in Germany is likely
to be within the range identified by using the results of
the published studies. Since ASHIP-data were also avail-
able for 2006 and patients can be tracked by unique
identifier, we were able to identify and include only
acute HZ cases in 2007 to prevent overestimation of
HZ-incidence. However, for 28% of HZ-cases in 2008
the classification as an acute case was not possible as we
were not able to track them in 2007 due to the different
regional datasets being available. This could cause a
slight overestimation of HZ-incidence in 2008. Finally,
the inpatient incidence might be slightly overestimated
when using the FHM database, since we were not able
to exclude non-acute HZ cases. An underestimation
might have occurred on the other hand, since inpatients
with HZ as a secondary diagnosis were not included in
our analysis, but still can contribute to prolonged hospi-
talizations and additional costs. However, the strength
of our study lies within the data sources we used. The
ASHIP database provides high-quality outpatient infor-
mation from a considerable proportion of the German
population and can be utilized in a cohort-design fash-
ion; the FHM-System provides data from a number of
databases in the German health care system.
Germany is one of the few countries worldwide where
routine childhood varicella vaccination is recommended,
with its initiation in 2004 and a change from a recom-
mended one-dose to a two-dose vaccination schedule in
2009 [42]. Mathematical modelling suggests that routine
childhood varicella vaccination will reduce VZV-circula-
tion in nature, which will decrease the number of nat-
ural boosters of VZV-immunity in the population.
According to mathematical models, this might lead to a
substantial increase in HZ-incidence in the population
for 40 to 50 years after the initiation of routine varicella
vaccination [43,44]. Since mathematical models are
based on many assumptions, it is important to closely
observe whether this phenomenon will occur in nature.
Since 2005 a physician sentinel-system is in place in
Germany to monitor the effects of the current varicella
vaccination recommendation [42]. As of today no clear
increase in reported HZ-cases per doctors’ practices has
been observed. But due to the lack of a proper denomi-
nator, HZ incidences can not be determined [42]. In the
United States, where a varicella vaccination program is
in place since 1995, various studies have as of yet also
not shown a clear effect of the program on HZ-inci-
dence, even though the incidence of varicella declined
rapidly [21,45].
To monitor potential changes in HZ-epidemiology,
countries with routine varicella vaccination should
assess HZ-incidence on a periodical basis. HZ incidence
and disease burden data presented in this manuscript
will serve as important baseline data, and subsequent
follow-up incidence data will not only be of critical
importance to the German health system, but also for
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Page 6 of 8other countries who have recently introduced or are
currently considering the introduction of routine child-
hood varicella vaccination.
Conclusions
Our study confirms the considerable disease burden that
HZ and PHN place on the German health care system.
With an aging population it is likely that HZ disease
burden will continue to increase in Germany, and the
implemented routine childhood varicella vaccination
program might contribute to an increase in disease bur-
den in the future as well. Our study provides important
baseline estimates of HZ-incidence in different age-
groups in Germany, which will be important also for the
development of a HZ vaccination recommendation. Fol-
low-up periodical analyses of ASHIP-data will be per-
formed to monitor the impact of varicella and herpes
zoster vaccination in Germany.
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